Evidence map›Paper›PMID 39367093›Full record

ArticleNature biotechnology2025

Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses.

Shaobo Yang, Michal Sheffer, Isabel E Kaplan, Zongqi Wang, Mubin Tarannum, Khanhlinh Dinh, Yasmin Abdulhamid, Eden Bobilev, Roman Shapiro, Rebecca Porter and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Shaobo Yang *Department of Bioengineering, Northeastern University, Boston, MA, USA.ORCID http://orcid.org/0009-0006-5257-6775
Michal Sheffer *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Isabel E KaplanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zongqi WangDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Mubin TarannumDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Khanhlinh DinhDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yasmin AbdulhamidDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eden BobilevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Roman ShapiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rebecca PorterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Robert SoifferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jerome RitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5526-4669
John KorethDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yun WeiDepartment of Chemistry and Chemical Engineering, Northeastern University, Boston, MA, USA.
Peiru ChenDepartment of Chemistry and Chemical Engineering, Northeastern University, Boston, MA, USA.
Ke ZhangDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Valeria Márquez-PellegrinDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Shanna BonannoDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Neel JoshiDepartment of Chemistry and Chemical Engineering, Northeastern University, Boston, MA, USA.
Ming GuanDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Mengdi YangDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Deng LiDepartment of Bioengineering, Northeastern University, Boston, MA, USA.ORCID http://orcid.org/0009-0002-3030-8009
Chiara BelliniDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Fuguo LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jianzhu ChenKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5687-6154
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jiahe LiDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. jiaheli@med.umich.edu.ORCID http://orcid.org/0000-0002-9889-8546
Rizwan RomeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. rizwan_romee@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-9077-4736

Funding

Enzymatic and genetic strategies for targeting disease-associated microbial metabolitesDP2GM154019 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li · 2023 to 2026
$2.3M
NIGMS NIH HHS DP2 GM154019
6 · The paper itself

Abstract

The tumor microenvironment can inhibit the efficacy of cancer therapies through mechanisms such as poor trafficking and exhaustion of immune cells. Here, to address this challenge, we exploited the safety, tumor tropism and ease of genetic manipulation of non-pathogenic Escherichia coli (E. coli) to deliver key immune-activating cytokines to tumors via surface display on the outer membrane of E. coli K-12 DH5α. Non-pathogenic E. coli expressing murine decoy-resistant IL18 mutein (DR18) induced robust CD8

Indexed as

Escherichia coliInterleukin-18Killer Cells, NaturalReceptors, Chimeric AntigenAnimalsCell Line, TumorFemaleHumansMesothelinMiceTumor MicroenvironmentXenograft Model Antitumor AssaysInterleukin-18MesothelinReceptors, Chimeric Antigen

Identifiers

PMID39367093
PMCPMC12797303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.